Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1

• Status: Withdrawn
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to investigate the effect of adjuvant therapy by Sorafenib, Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver transplantation

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhejiang University
• Treatments: Niacinamide; Oxaliplatin; Sorafenib

Criteria

Inclusion Criteria:

• hepatocellular carcinoma after liver transplantation

• Major organ (heart, lung and brain) function was normal

Exclusion Criteria:

• Any active infectious process

• The presence of clinically confirmed extrahepatic metastasis

• Postoperative dysfunction of any organ